PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA

$0M01FY2001RRNIH

Stanford University, Stanford CA

Investigators

Linked publications & trials

Paper 38684815 Paper 35728925 Paper 33478957 Paper 33277303 Paper 32446491 Paper 32171899 Paper 32111975 Paper 31691959 Paper 31600550 Paper 31427096 Paper 30631138 Paper 30531941 Paper 30239722 Paper 30224653 Paper 29872859 Paper 29641994 Paper 29479291 Paper 29141982 Paper 28923095 Paper 28283553 Paper 28279433 Paper 28199816 Paper 27544837 Paper 27455401 Paper 27423510 Paper 26908487 Paper 26638192 Paper 26209223 Paper 26091977 Paper 26080344 Paper 26070913 Paper 25886831 Paper 25601310 Paper 25577655 Paper 25474559 Paper 25455511 Paper 25425651 Paper 25348129 Paper 25183760 Paper 25023551 Paper 24819305 Paper 24790261 Paper 24767622 Paper 24755714 Paper 24622517 Paper 24615880 Paper 24570214 Paper 24405552 Paper 24398043 Paper 24378638 Paper 24370654 Paper 24367114 Paper 24322171 Paper 24296717 Paper 24220913 Paper 24135709 Paper 24074694 Paper 23955431 Paper 23943230 Paper 23867958 Paper 23867957 Paper 23849514 Paper 23712984 Paper 23649774 Paper 23633217 Paper 23591775 Paper 23471015 Paper 23441606 Paper 23418430 Paper 23352957 Paper 23212606 Paper 23127215 Paper 23085787 Paper 23043681 Paper 22990746 Paper 22926660 Paper 22863642 Paper 22831182 Paper 22814942 Paper 22770543 Paper 22748517 Paper 22727477 Paper 22684193 Paper 22644414 Paper 22562288 Paper 22499082 Paper 22481243 Paper 22371027 Paper 22361517 Paper 22344233 Paper 22199011 Paper 22057854 Paper 22057853 Paper 22025567 Paper 21960671 Paper 21933176 Paper 21930284 Paper 21873835 Paper 21865361 Paper 21855408

Abstract

Both radioimmunotherapy and the unlabeled monoclonal antibody, rituximab, have clinical activity in low-grade lymphomas. Theoretically, patients who have been previously treated with rituximab may mount an immune response that would preclude subsequent uses of other antibody treatments. This study is being performed to determine the activity and safety of Iodine-131 Anti-B1 Antibody therapy in patients who have been previously treated with the anti-CD20 monoclonal antibody, rituximab.

View original record on NIH RePORTER →